Andersson Martin, Johansson Lennart, Eckerman Keith, Mattsson Sören
Medical Radiation Physics, Department of Translational Medicine, Malmö, Lund University, Skåne University Hospital, SE-205 02, Malmö, Sweden.
Radiation Physics, Department of Radiation Sciences, Umeå University, SE-901 87, Umeå, Sweden.
EJNMMI Res. 2017 Nov 3;7(1):88. doi: 10.1186/s13550-017-0339-3.
To date, the estimated radiation-absorbed dose to organs and tissues in patients undergoing diagnostic examinations in nuclear medicine is derived via calculations based on models of the human body and the biokinetic behaviour of the radiopharmaceutical. An internal dosimetry computer program, IDAC-Dose2.1, was developed based on the International Commission on Radiological Protection (ICRP)-specific absorbed fractions and computational framework of internal dose assessment given for reference adults in ICRP Publication 133. The program uses the radionuclide decay database of ICRP Publication 107 and considers 83 different source regions irradiating 47 target tissues, defining the effective dose as presented in ICRP Publications 60 and 103. The computer program was validated against another ICRP dosimetry program, Dose and Risk Calculation (DCAL), that employs the same computational framework in evaluation of occupational and environmental intakes of radionuclides. IDAC-Dose2.1 has a sub-module for absorbed dose calculations in spherical structures of different volumes and composition; this sub-module is intended for absorbed dose estimates in radiopharmaceutical therapy. For nine specific alpha emitters, the absorbed dose contribution from their decay products is also included in the committed absorbed dose calculations.
The absorbed doses and effective dose of I-iodide determined by IDAC-Dose2.1 were validated against the dosimetry program DCAL, showing identical results. IDAC-Dose2.1 was used to calculate absorbed doses for intravenously administered F-FDG and orally administered Tc-pertechnetate and I-iodide, three frequently used radiopharmaceuticals. Using the tissue weighting factors from ICRP Publication 103, the effective dose per administered activity was estimated to be 0.016 mSv/MBq for F-FDG, 0.014 mSv/MBq for Tc-pertechnetate, and 16 mSv/MBq for I-iodide.
The internal dosimetry program IDAC-Dose2.1 was developed and applied to three radiopharmaceuticals for validation against DCAL and to generate improved absorbed dose estimations for diagnostic nuclear medicine using specific absorbed fraction values of the ICRP computational voxel phantoms. The sub-module for absorbed dose calculations in spherical structures 1 mm to 9 cm in diameter and different tissue composition was included to broaden the clinical usefulness of the program. The IDAC-Dose2.1 program is free software for research and available for download at http://www.idac-dose.org .
迄今为止,核医学诊断检查患者器官和组织的估计辐射吸收剂量是通过基于人体模型和放射性药物生物动力学行为的计算得出的。基于国际放射防护委员会(ICRP)特定吸收分数以及ICRP第133号出版物中给出的参考成年人内部剂量评估计算框架,开发了内部剂量学计算机程序IDAC-Dose2.1。该程序使用ICRP第107号出版物的放射性核素衰变数据库,考虑83个不同源区域对47个靶组织的照射,按照ICRP第60号和第103号出版物中的定义确定有效剂量。该计算机程序针对另一个ICRP剂量学程序“剂量与风险计算(DCAL)”进行了验证,DCAL在评估放射性核素的职业和环境摄入量时采用相同的计算框架。IDAC-Dose2.1有一个用于计算不同体积和组成的球形结构中吸收剂量的子模块;该子模块旨在用于放射性药物治疗中的吸收剂量估计。对于九种特定的α发射体,其衰变产物对吸收剂量的贡献也包含在待积吸收剂量计算中。
IDAC-Dose2.1确定的碘-131的吸收剂量和有效剂量与剂量学程序DCAL进行了验证,结果相同。IDAC-Dose2.1用于计算静脉注射氟代脱氧葡萄糖(F-FDG)、口服高锝酸盐(Tc)和碘-131这三种常用放射性药物的吸收剂量。使用ICRP第103号出版物中的组织权重因子,每单位给药活度的有效剂量估计为:F-FDG为0.016 mSv/MBq,高锝酸盐为0.014 mSv/MBq,碘-131为16 mSv/MBq。
开发了内部剂量学程序IDAC-Dose2.1,并将其应用于三种放射性药物,以与DCAL进行验证,并使用ICRP计算体素模型的特定吸收分数值生成改进的诊断核医学吸收剂量估计值。包含了用于计算直径1毫米至9厘米且具有不同组织组成的球形结构中吸收剂量的子模块,以扩大该程序的临床实用性。IDAC-Dose2.1程序是免费的研究软件,可从http://www.idac-dose.org下载。